Unknown

Dataset Information

0

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.


ABSTRACT: KRAS is one of the most frequently mutated proto-oncogenes in human cancers. The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers. The consistency, frequency, and tumor specificity of these "neoantigens" make them attractive therapeutic targets. Recent data associate T cells that target mutated antigens with clinical immunotherapy responses in patients with metastatic melanoma, lung cancer, or cholangiocarcinoma. Using HLA-peptide prediction algorithms, we noted that HLA-A*11:01 could potentially present mutated KRAS variants. By immunizing HLA-A*11:01 transgenic mice, we generated murine T cells and subsequently isolated T-cell receptors (TCR) highly reactive to the mutated KRAS variants G12V and G12D. Peripheral blood lymphocytes (PBL) transduced with these TCRs could recognize multiple HLA-A*11:01(+) tumor lines bearing the appropriate KRAS mutations. In a xenograft model of large established tumor, adoptive transfer of these transduced PBLs reactive with an HLA-A*11:01, G12D-mutated pancreatic cell line could significantly reduce its growth in NSG mice (P = 0.002). The success of adoptive transfer of TCR-engineered T cells against melanoma and other cancers supports clinical trials with these T cells that recognize mutated KRAS in patients with a variety of common cancer types.

SUBMITTER: Wang QJ 

PROVIDER: S-EPMC4775432 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.

Wang Qiong J QJ   Yu Zhiya Z   Griffith Kayla K   Hanada Ken-ichi K   Restifo Nicholas P NP   Yang James C JC  

Cancer immunology research 20151223 3


KRAS is one of the most frequently mutated proto-oncogenes in human cancers. The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers. The consistency, frequency, and tumor specificity of these "neoantigens" make them attractive therapeutic targets. Recent data associate T cells that target mutated antigens with clinical immunotherapy responses in patients  ...[more]

Similar Datasets

| S-EPMC5094194 | biostudies-literature
| S-EPMC9324032 | biostudies-literature
| S-EPMC5448175 | biostudies-literature
| S-EPMC7226330 | biostudies-literature
| S-EPMC11228449 | biostudies-literature
| S-EPMC8147792 | biostudies-literature
| S-EPMC6966533 | biostudies-literature
| S-EPMC6122969 | biostudies-literature
2024-09-14 | E-MTAB-12171 | biostudies-arrayexpress
| S-EPMC4839821 | biostudies-other